Novo Nordisk and Glooko launch diabetes management app

New digital health partners Novo Nordisk and Glooko have released their first joint diabetes-focused app.

The Cornerstones4Care (C4C) Powered by Glooko mobile app aims to help people manage their diabetes by letting them measure and track their blood glucose, activity and meals all in one place.

According to the companies, the app is compatible with the majority of currently available diabetes and exercise devices which will sync blood glucose and activity data to the app.

The app can then use this data to provide recommendations to diabetes patients to help better manage their condition. This includes resources provided by Novo Nordisk’s Cornerstones4Care support programme.

"More people than ever are using mobile apps for chronic disease management, and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data,” said Rick Altinger, CEO of Glooko.

C4C will act as a framework for future jointly-developed digital tools from Novo Nordisk and Glooko as part of the ongoing collaboration struck between the two in January.

The collaboration intends to combine Glooko’s digital app presence with Novo Nordisk’s extensive knowledge of the diabetes pharmaceutical market.

The self-titled Glooko app is sold as a remote monitoring tool for hospitals, as well as a patient-aimed self-management app.

It is one of many companies looking to leverage digital tools to advance diabetes care. One of its biggest competitors is mySugr – a Swiss firm that provides its own diabetes resources alongside similar blood glucose device interoperability.

The company was recently acquired by Novo Nordisk competitor Roche for an undisclosed fee.

The two companies had been working together since 2015 and had extended their partnership earlier this year on the back of impressive real-world data related to the app’s use.